New Fast Track Designation for ENDO DX tool

Up to 1 in 10 reproductive-aged women are impacted by endometriosis. Dysmenorrhea is the most common pelvic complaint of adolescents. While most cases of primary dysmenorrhea in adolescents will be primary dysmenorrhea, Endo remains a possibility especially after 2-3 years of progressive symptoms. Although the true prevalence of endometriosis in adolescents is unknown, at least two thirds of adolescent girls with chronic pelvic pain or dysmenorrhea unresponsive to hormonal therapies and NSAIDs will be diagnosed with endometriosis at the time of diagnostic laparoscopy. Now, as of July 2, 2024, a new diagnostic tool for Endo has received FDA Fast Track designation for development. This is different than FDA APPROVAL, but still represents a novel new option (if/when approved) to make ENDO diagnosis possible by using a molecular/protein ligand tracer. Listen in for details!